Aardvark Therapeutics (NASDAQ:AARD) reported quarterly losses of $(0.99) per share which missed the analyst consensus estimate of $(0.90) by 10 percent. This is a 39.44 percent decrease over losses of $(0.71) per share from the same period last year.